Recombinant
RabMAb

Recombinant Anti-Argininosuccinate Lyase antibody [EPR19382] (ab201025)

Overview

  • Product name

    Anti-Argininosuccinate Lyase antibody [EPR19382]
    See all Argininosuccinate Lyase primary antibodies
  • Description

    Rabbit monoclonal [EPR19382] to Argininosuccinate Lyase
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IPmore details
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Recombinant fragment within Human Argininosuccinate Lyase aa 1 to the C-terminus. The exact sequence is proprietary.
    Database link: P04424

  • Positive control

    • WB: Human fetal heart, fetal kidney, fetal spleen and fetal liver lysates; HepG2 untreated and treated with 1 µM dexamethasone for 24 hours whole cell lysates; HEK-293 HeLa, T-47D, A549 and SH-SY5Y whole cell lysates. IP: Human fetal liver whole cell lysate.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab201025 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000. Detects a band of approximately 51 kDa (predicted molecular weight: 51 kDa).
IP 1/40.

Target

  • Pathway

    Amino-acid biosynthesis; L-arginine biosynthesis; L-arginine from L-ornithine and carbamoyl phosphate: step 3/3.
    Nitrogen metabolism; urea cycle; L-arginine and fumarate from (N(omega)-L-arginino)succinate: step 1/1.
  • Involvement in disease

    Defects in ASL are the cause of arginosuccinicaciduria (ARGINSA) [MIM:207900]. Arginosuccinicaciduria is an autosomal recessive disorder of the urea cycle. The disease is characterized by mental and physical retardation, liver enlargement, skin lesions, dry and brittle hair showing trichorrhexis nodosa microscopically and fluorescing red, convulsions, and episodic unconsciousness.
  • Sequence similarities

    Belongs to the lyase 1 family. Argininosuccinate lyase subfamily.
  • Post-translational
    modifications

    Acetylation modifies enzyme activity in response to alterations of extracellular nutrient availability. Acetylation increased with trichostin A (TSA) or with nicotinamide (NAM). Glucose increases acetylation by about a factor of 3 with decreasing enzyme activity. Acetylation on Lys-288 is decreased on the addition of extra amino acids resulting in activation of enzyme activity.
  • Information by UniProt
  • Database links

  • Alternative names

    • Argininosuccinase antibody
    • Argininosuccinate lyase antibody
    • Arginosuccinase antibody
    • ARLY_HUMAN antibody
    • ASAL antibody
    • ASL antibody
    • EC 4.3.2.1 antibody
    see all

Images

  • All lanes : Anti-Argininosuccinate Lyase antibody [EPR19382] (ab201025) at 1/1000 dilution

    Lane 1 : Human fetal heart lysate
    Lane 2 : Human fetal kidney lysate
    Lane 3 : Human fetal spleen lysate
    Lane 4 : Human fetal liver lysate

    Lysates/proteins at 10 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG Peroxidase Conjugate, specific to the non-reduced form of IgG at 1/100000 dilution

    Predicted band size: 51 kDa
    Observed band size: 51 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure time: Lane 1,2 and 3: 8 seconds; Lane 4: 1 second.

  • All lanes : Anti-Argininosuccinate Lyase antibody [EPR19382] (ab201025) at 1/1000 dilution

    Lane 1 : Untreated HepG2 (Human liver hepatocellular carcinoma cell line) whole cell lysate
    Lane 2 : HepG2 (Human liver hepatocellular carcinoma cell line) treated with 1 µM dexamethasone for 24 hours whole cell lysate
    Lane 3 : HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate
    Lane 4 : HeLa (Human epithelial cell line from cervix adenocarcinoma) whole cell lysate
    Lane 5 : T-47D (Human ductal breast epithelial tumor cell line) whole cell lysate
    Lane 6 : A549 (Human lung carcinoma cell line) whole cell lysate
    Lane 7 : SH-SY5Y (Human neuroblastoma cell line from bone marrow) whole cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution

    Predicted band size: 51 kDa
    Observed band size: 51 kDa



    Blocking/Dilution buffer: 5% NFDM/TBST.

    Exposure time: Lane 1 and 2: 1 second; Lane 3,4 and 5: 15 seconds; Lane 6 and 7: 30 seconds.

    Dexamethasone treatment increase the accumulation of ASL mRNA (PMID: 2209616).

  • Argininosuccinate Lyase was immunoprecipitated from 1mg of Human fetal liver whole cell lysate with ab201025 at 1/40 dilution.

    Western blot was performed from the immunoprecipitate using ab201025 at 1/1000 dilution.

    VeriBlot for IP Detection Reagent (HRP) (ab131366), was used for detection at 1/10000 dilution.

    Lane 1: Human fetal liver whole cell lysate, 10µg (Input).

    Lane 2: ab201025 IP in Human fetal liver whole cell lysate.

    Lane 3: Rabbit IgG,monoclonal-Isotype Control (ab172730) instead of ab201025 in Human fetal liver whole cell lysate.

    Blocking and dilution buffer and concentration: 5% NFDM/TBST.

    Exposure time: 5 seconds.

References

ab201025 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab201025.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up